An aberrant gene fusion echinoderm microtubule–associated protein-like 4-anaplastic lymphoma kinase occurs in 2% to 7% of worldwide non–small-cell lung cancers (NSCLC), encoding a cytoplasmic chimeric protein with constitutive kinase activity. In France, ALK rearrangement detected by fluorescence in situ hybridization (FISH) is observed in 3.7% of patients with advanced nonsquamous NSCLC.
1 x 1 Barlesi, F, Blons, H, Beau-Faller, M et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2013; 31 (abstr 8000) Crossref | Scopus (162) | Google Scholar See all References The prevalence of ALK rearrangement is increased in young nonsmoker/light-smoker and adenocarcinoma patients. Crizotinib, an oral small-molecule tyrosine kinase inhibitor targeting ALK, MET, and ROS1 tyrosine kinases, has proven to exhibit a marked antitumor activity in ALK-rearranged NSCLC. Its efficacy has been evaluated in three multinational trials, namely two uncontrolled phase I/II and II studies (PROFILE 1001
2 x 2 Kwak, EL, Bang, YJ, Camidge, DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693–1703 Crossref | PubMed | Scopus (3007) | Google Scholar See all References and PROFILE 1005
3 x 3 Crinò, L, Kim, D, Riely, GJ et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011; 29 (abstr 7514) PubMed | Google Scholar See all References ) and a randomized controlled phase III study comparing crizotinib with single-agent pemetrexed or docetaxel in previously treated patients (PROFILE 1007
4 x 4 Shaw, AT, Kim, DW, Nakagawa, K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385–2394 Crossref | PubMed | Scopus (1825) | Google Scholar See all References ). The drug’s efficacy has been recently confirmed in a randomized controlled phase III study comparing crizotinib with cisplatin/pemetrexed doublet chemotherapy in first-line setting (PROFILE 1014).
5 x 5 Solomon, BJ, Mok, T, Kim, DW et al. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371: 2167–2177 Crossref | PubMed | Scopus (1088) | Google Scholar See all References These results have led to crizotinib approval for first-line and second- or more-line treatment of ALK-positive advanced NSCLC patients in the United States and Europe, respectively.